Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Venetoclax

Tundra lists 3 Venetoclax clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT07238907

A Multi-center Retrospective Study of INO Treating B-ALL

This multi-center retrospective study aims to evaluate the efficacy and safety of inotuzumab ozogamicin in adults B-ALL of different subgroups. This study is a retrospective study. Data will be collected from Electronic Medical Record, interventions will not be implemented on patients.

Gender: All

Ages: 16 Years - 80 Years

Updated: 2025-11-25

1 state

Acute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemias (ALL)
Inotuzumab Ozogamicin
+1
ACTIVE NOT RECRUITING

NCT05996406

Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)

Venetoclax is considered as a promising agent for light-chain (AL) amyloidosis due to the high percentage of t(11;14). Several retrospective studies showed venetoclax-based therapy could induce rapid and profound hematologic response in AL patients with favorable safety profile. As an oral agent with encouraging data, it is worth to prospectively evaluate the efficacy and safety of venetoclax in untreated AL amyloidosis patients.

Gender: All

Ages: 18 Years - Any

Updated: 2025-01-22

Light Chain (AL) Amyloidosis
CCND1 Translocation
Venetoclax
RECRUITING

NCT05841771

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

The main objective of the study is to evaluate the efficacy and safety of maintenance therapy with hypomethylating agent and Venetoclax to improve leukemia free survival for high-risk myeloid malignancies after allogeneic hematopoietic stem cell transplantation .

Gender: All

Ages: 18 Years - 70 Years

Updated: 2024-08-09

1 state

Hypomethylating Agent
Venetoclax
Myeloid Malignancy